SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA

Dytfeld, Dominik; Radocha, Jakub; Hajek, Roman; CENGİZ SEVAL, GÜLDANE; Berkac, Meral; Coriu, Daniel; Derman, Benjamin; Jakubowiak, Andrzej; Peceliunas, Valdas; Mikala, Gabor; Bołkun, Łukasz; Hawrylecka, Dorota; Grosicki, Sebastian; Tyczyńska, Agata; Zaucha, Jan; Knopińska, Wanda; Semeńczuk, Grażyna; Morawska, Marta; Giannopoulos, Krzysztof; Puła, Anna; Rymko, Marcin; Charliński, Grzegorz; Szeremet, Agnieszka; Kalicińska, Elżbieta; Usnarska, Lidia; Wróbel, Tomasz; Jamroziak, Krzysztof; Druzd-Sitek, Agnieszka; Romejko-Jarosińska, Joanna; Sawicki, Waldemar; Waszczuk-Gajda, Anna; Juda, Adrian; Hus, Marek; Gil, Lidia

doi:10.5603/ahp.a2023.0016

SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA

Dytfeld D., Radocha J., Hajek R., CENGİZ SEVAL G., Berkac M., Coriu D., ...More

Acta Haematologica Polonica, vol.54, no.2, pp.82-85, 2023 (Scopus)

Publication Type: Article / Article
Volume: 54 Issue: 2
Publication Date: 2023
Doi Number: 10.5603/ahp.a2023.0016
Journal Name: Acta Haematologica Polonica
Journal Indexes: Scopus, BIOSIS, Central & Eastern European Academic Source (CEEAS), EMBASE
Page Numbers: pp.82-85
Keywords: COVID-19, myeloma
Ankara University Affiliated: Yes

Abstract

Introduction: Despite several studies, the impact of coronavirus disease 2019 on patients with multiple myeloma remains uncertain. Material and methods: We performed a survey that covered the period of the first and second waves of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 23 centers inseven countries. Out of 352 patients with myeloma and SARS-CoV-2, 23% died. Results/Conclusions: Logistic regression showed a lower risk of death among patients treated with proteasome inhibitor and a higher risk of death for those who had a severe or a very severe course of disease.